Graft versus leukemia. VI. Adoptive immunotherapy in combination with chemoradiotherapy for spontaneous leukemia-lymphoma in AKR mice.
A three-step treatment plan incorporating adoptive immunotherapy and chemoradiotherapy was used to treat AKR (H-2k) mice bearing spontaneous leukemia-lymphoma (SLL). 1) Leukemic mice were treated with chemoradiotherapy for immunosuppression and leukemia cytoreduction. 2) To introduce a graft-versus-leukemia reaction against residual malignant cells, the immunosuppressed AKR mice were given immunocompetent cells from H-2 mismatched DBA/2 (H-2d) donors. 3) To "rescue" the AKR hosts from incipient graft-versus-host disease, the mismatched DBA/2 cells were killed with combination chemotherapy, and cells from allogeneic H-2 matched RF (H-2k) donors were administered to restore hematopoiesis. Leukemic AKR mice thus treated had significant prolongation of their median survival time and a higher 60-day survival rate post treatment than did untreated controls, chemoradiotherapy controls, or control mice that received chemoradiotherapy plus cells from syngeneic donors. Therefore, adoptive immunotherapy may be useful as an adjunct to conventional therapy for treatment of SLL in AKR mice.
D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000912:Antibodies, Neoplasm; D003520:Cyclophosphamide / Q000627:therapeutic use; D006087:Graft vs Host Reaction / Q000188:drug therapy*; D007116:Immunization, Passive; D007942:Leukemia, Experimental / Q000188:drug therapy / Q000276:immunology / Q000532:radiotherapy / Q000628:therapy*; D008130:Lomustine / Q000627:therapeutic use; D051379:Mice; D008806:Mice, Inbred AKR
D000912:Antibodies, Neoplasm; D008130:Lomustine; D000666:Amphotericin B; D003520:Cyclophosphamide